Breaking News Instant updates and real-time market news.

VRNA

Verona Pharma

$6.42

(0.00%)

04:55
04/25/19
04/25
04:55
04/25/19
04:55

Verona Pharma management to meet with SunTrust

Meeting to be held in New York on April 25 hosted by SunTrust.

  • 25

    Apr

VRNA Verona Pharma
$6.42

(0.00%)

01/14/19
WEDB
01/14/19
NO CHANGE
Target $56
WEDB
Outperform
Wedbush says time to buy Verona Pharma, reaction to 3 day combo Phase 2 overdone
Wedbush analyst analyst is Liana Mousssatos notes that Verona Pharma is developing Ensifentrine as a treatment candidate for respiratory diseases such as COPD, CF and potentially asthma, and multiple exploratory Phase 2 trials for COPD have been conducted with the latest testing this new mechanism on top of dual LAMA/LABA and triple background therapy. The analyst adds that topline results were reported and speculates the negative overreaction in stock value is due to the lack of statistical significance for the primary endpoint. While Moussatos acknowledges that lack of statistical significance is "annoying," she believes it is not a deal-breaker for approval. The analyst sees that while the high dose contributed to the lack of statistical significance for the primary endpoint, the low dose has a consistently positive effect in the various analyses and may be a dose used in a future Phase 3 trial. Moussatos considers the weakness to be a buying opportunity, and reiterates an Outperform rating and $56 price target on the shares.
04/17/19
BTIG
04/17/19
INITIATION
BTIG
Buy
Verona Pharma initiated with a Buy at BTIG
04/17/19
BTIG
04/17/19
INITIATION
Target $17
BTIG
Buy
Verona Pharma initiated with a Buy at BTIG
BTIG analyst Thomas Shrader initiated Verona Pharma with a Buy rating and a price target of $17, citing the company's development of RPL554 for Chronic Obstructive Pulmonary Disease, which he sees as an "enormous and underserved market of about 16M patients in the U.S." The analyst states that while the market for COPD treatment is "crowded with bronchodilators", he sees Verona Phama's "highly active and patient-friendly anti-inflammatory drug like RPL554" as an important advance and looks ahead to its pivotal trial study that may begin later this year.

TODAY'S FREE FLY STORIES

PGSVY

PGS ASA

$0.00

(0.00%)

05:33
06/20/19
06/20
05:33
06/20/19
05:33
Downgrade
PGS ASA rating change  »

PGS ASA downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PDD

Pinduoduo

$20.96

0.08 (0.38%)

05:32
06/20/19
06/20
05:32
06/20/19
05:32
Initiation
Pinduoduo initiated  »

Pinduoduo initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CB

Chubb

$148.73

1.37 (0.93%)

05:30
06/20/19
06/20
05:30
06/20/19
05:30
Downgrade
Chubb rating change  »

Chubb downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

OPHLY

Ono Pharmaceutical

$0.00

(0.00%)

05:29
06/20/19
06/20
05:29
06/20/19
05:29
Downgrade
Ono Pharmaceutical rating change  »

Ono Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YARIY

Yara

$0.00

(0.00%)

05:27
06/20/19
06/20
05:27
06/20/19
05:27
Downgrade
Yara rating change  »

Yara downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZURVY

Zurich Insurance

$0.00

(0.00%)

05:26
06/20/19
06/20
05:26
06/20/19
05:26
Upgrade
Zurich Insurance rating change  »

Zurich Insurance upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRE

Bank of Ireland

$0.00

(0.00%)

05:24
06/20/19
06/20
05:24
06/20/19
05:24
Upgrade
Bank of Ireland rating change  »

Bank of Ireland upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DOC

Physicians Realty Trust

$18.27

0.095 (0.52%)

05:23
06/20/19
06/20
05:23
06/20/19
05:23
Initiation
Physicians Realty Trust initiated  »

Physicians Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HTA

Healthcare Trust

$29.18

0.16 (0.55%)

05:23
06/20/19
06/20
05:23
06/20/19
05:23
Initiation
Healthcare Trust initiated  »

Healthcare Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

HR

Healthcare Realty Trust

$33.14

0.26 (0.79%)

05:22
06/20/19
06/20
05:22
06/20/19
05:22
Initiation
Healthcare Realty Trust initiated  »

Healthcare Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

SCRYY

Scor

$0.00

(0.00%)

05:22
06/20/19
06/20
05:22
06/20/19
05:22
Upgrade
Scor rating change  »

Scor upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMS

Fresenius Medical

$39.49

1.175 (3.07%)

05:20
06/20/19
06/20
05:20
06/20/19
05:20
Upgrade
Fresenius Medical rating change  »

Fresenius Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPQ

HP Inc.

$20.63

0.1 (0.49%)

05:16
06/20/19
06/20
05:16
06/20/19
05:16
Initiation
HP Inc. initiated  »

Deutsche Bank starts HP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 01

    Jul

  • 02

    Jul

  • 03

    Jul

  • 04

    Jul

DELL

Dell Technologies

$53.39

1.88 (3.65%)

05:15
06/20/19
06/20
05:15
06/20/19
05:15
Initiation
Dell Technologies initiated  »

Deutsche Bank starts Dell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

FNMA

Fannie Mae

05:12
06/20/19
06/20
05:12
06/20/19
05:12
Initiation
Fannie Mae initiated  »

Fannie Mae initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMCC

Freddie Mac

$0.00

(0.00%)

05:12
06/20/19
06/20
05:12
06/20/19
05:12
Initiation
Freddie Mac initiated  »

Freddie Mac initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$197.87

-0.65 (-0.33%)

05:12
06/20/19
06/20
05:12
06/20/19
05:12
Initiation
Apple initiated  »

Deutsche Bank, fearing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JBLU

JetBlue

$19.05

-0.21 (-1.09%)

05:07
06/20/19
06/20
05:07
06/20/19
05:07
Recommendations
JetBlue analyst commentary  »

JetBlue price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VYGR

Voyager Therapeutics

$27.87

0.05 (0.18%)

, SNY

Sanofi

$44.11

0.99 (2.30%)

05:05
06/20/19
06/20
05:05
06/20/19
05:05
Recommendations
Voyager Therapeutics, Sanofi, Neurocrine analyst commentary  »

Voyager Therapeutics…

VYGR

Voyager Therapeutics

$27.87

0.05 (0.18%)

SNY

Sanofi

$44.11

0.99 (2.30%)

NBIX

Neurocrine

$85.47

-0.28 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 16

    Sep

ORCL

Oracle

$52.69

-0.19 (-0.36%)

05:02
06/20/19
06/20
05:02
06/20/19
05:02
Recommendations
Oracle analyst commentary  »

Oracle price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BFAM

Bright Horizons

$141.18

1.73 (1.24%)

04:59
06/20/19
06/20
04:59
06/20/19
04:59
Upgrade
Bright Horizons rating change  »

Bright Horizons upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENBL

Enable Midstream

04:56
06/20/19
06/20
04:56
06/20/19
04:56
Initiation
Enable Midstream initiated  »

Enable Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GHDX

Genomic Health

$54.26

-0.04 (-0.07%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Upgrade
Genomic Health rating change  »

Genomic Health upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

SMG

Scotts Miracle-Gro

$98.53

0.4 (0.41%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
Scotts Miracle-Gro management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 21

    Jun

04:55
06/20/19
06/20
04:55
06/20/19
04:55
General news
Jobless Claims to be reported at 08:30 »

Week of 6/15 Jobless…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.